ClinicalTrials.gg
CompletedNCT04927234Updated Oct 7, 2026Results posted

Foot and Ankle Post-operative Oedema Management Using Geko™

An interventional study of geko™ therapy in Surgery and Edema, sponsored by Firstkind Ltd. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Firstkind Ltd (part of Sky Medical Technology) · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Edema with a site in Spain — 2 open to participants now, 2 under way, none of them phase 3. Edema · Spain.

Started
2022
with 1 other
No phase
3 of 13
1 open now
Registered
9th of 13
by date
Lead sponsor
1 of 13
Firstkind Ltd

Among the 13 studies in Edema with a site in Spain, this one is one of 2 that started in 2022, is one of 3 with no phase, and was the 9th registered.

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

Browse Edema studies →

Open to participants now

2 of the 13 studies in Edema with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Edema with a site in Spain, or all of them as a file.
02

Study summary

The multicentre randomised geko™ Foot and Ankle Trial will prospectively and systematically collect clinical data on patients randomised, on a 1:1 basis, to either standard care or standard care plus geko™ therapy to assess oedema management and patient outcomes during a follow-up period of up to three months post-surgery.

Read the detailed description

The geko™ device has a wide range of clinical applications including the post-operative management of oedema.

Although many short-term acute studies have been completed using the device, little clinical data has been collected on the effect of geko™ use in current standard care pathways for oedema management on patient outcomes during long term follow-up after surgery.

This study is an open label, multi-centre prospective randomised study. The study patient population will be randomised on a 1:1 basis into two groups of 61 patients each. These groups are defined as Group A patients who receive geko™ therapy and SC i.e. the intervention group and Group B patients who receive Standard Care (SC) only i.e. no intervention. The participants will be assessed pre-surgery and up to 90 days post-surgery.

03

Conditions studied

  • Surgery
  • Edema

Browse trials for

Keywords

  • geko
  • foot surgery
  • ankle surgery
  • oedema management
  • post-operative oedema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years
  • Intact healthy skin at the site of geko™ device application.
  • Patients that have been listed for forefoot and / or hindfoot surgery
  • Patient understands and is willing to participate in the study and can comply with study procedures
  • Patient is willing and able to give written

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Use of any other neuro-modulation device.
  • Trauma to the lower limbs that would prevent geko™ from stimulating the common peroneal nerve.
  • No response to geko™ therapy i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting
  • Participation in any other clinical study that may interfere with the outcome of either study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Standard of care + geko™ Therapy

    In addition to their standard of care, for patients randomised to the intervention arm, geko™ therapy will be applied immediately post-surgery on the operated leg and administered for 24 hours / day whilst the patient remains in hospital, after which geko™ therapy will then be applied for 12hrs / day until the patient returns for their first post-operative follow-up visit (Day 14 ± 2 days post-surgery)

    Device: geko™ therapy

  • No intervention
    Standard of care

    Patients will receive their standard of care as per hospital practice.

Interventions

  • Devicegeko™ therapy

    Neuro-muscular electrical stimulation of the peroneal nerve

    Also known as: geko, NMES

06

What researchers measure

Primary outcomes

  1. Assessment of Post-operative Oedema Formation Using the Figure-of-eight Tape Measurement

    To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery. This will be done using the figure of eight tape measurement method

    Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op

  2. Assessment of Post-operative Oedema Formation Using the Pitting Oedema Scale

    To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using the pitting oedema scale, where following a 2 second firm thumb press, 0 (min) indicates no oedema and 4 (max) is a very deep pit.

    Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op

  3. Assessment of Post-operative Oedema Formation Using Bioimpedance Analysis (US Sites Only)

    To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using a bioimpedance device to measure resistance to electrical current in both legs and calculating the percentage difference between the operated leg and the contralateral limb.

    Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op

Secondary outcomes

  1. Adverse Events

    Incidence of Adverse Events in each group

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

  2. Device Deficiencies

    To assess the number of geko device deficiencies (if any)

    Time frame: from start of geko treatment (immediately post-surgery) until up to 90 days post-surgery

  3. Change in Pain Level Using a Visual Analogue Scale (VAS) Score

    Assessing pain levels using a visual analogue scale (VAS) score, where 0mm means no pain and 100mm is the worst pain possible.

    Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op

  4. Surgical Wound Healing

    Visually assessing the surgical wound healing status as either healed/progressing/static/deteriorating/severe.

    Time frame: From surgery until up to 90 days post-surgery

  5. Change in Analgesia Dosage

    Assessing changes in dosage of recorded analgesic medication taken by the patient

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

  6. Change in Analgesia Frequency

    Analgesic medication use was recorded; however, participants were not asked to record the frequency of use. Therefore, frequency of analgesic use could not be analysed.

    Time frame: From pre-surgery assessment until up to 90 days post-surgery

  7. Change in Patient Reported Outcomes Via Manchester-Oxford Foot & Ankle Questionnaire (MOxFQ)

    Domains that are assessed in this questionnaire include walking/standing, pain and social interaction. Scores will range from 0 to 100, where 100 is most severe.

    Time frame: Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op

07

Results

Posted Oct 7, 2026

Participant flow

Participant flow — Overall Study
MilestoneStandard of Care + Geko™ TherapyStandard of Care
Started5853
Completed4335
Not completed1518

Outcome measures

PrimaryAssessment of Post-operative Oedema Formation Using the Figure-of-eight Tape Measurement

To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery. This will be done using the figure of eight tape measurement method

Time frame:
Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Reported as:
Mean · cm
Assessment of Post-operative Oedema Formation Using the Figure-of-eight Tape Measurement
cmStandard of Care + Geko™ TherapyStandard of Care
Baseline-pre-op52.51 ± 0.752.49 ± 0.56
FU1- Day 14 post-op53.74 ± 0.8154.9 ± 0.82
FU2- Day 42 post-op52.74 ± 0.7453.97 ± 0.76
FU3- Day 90 post-op52.75 ± 0.6753.37 ± 0.7
Statistical analysis
  • Standard of Care + Geko™ Therapy vs Standard of Care · t-test, 2 sided · p = 0.98
  • Standard of Care + Geko™ Therapy vs Standard of Care · t-test, 2 sided · p = 0.32
PrimaryAssessment of Post-operative Oedema Formation Using the Pitting Oedema Scale

To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using the pitting oedema scale, where following a 2 second firm thumb press, 0 (min) indicates no oedema and 4 (max) is a very deep pit.

Time frame:
Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Reported as:
Mean · score
Assessment of Post-operative Oedema Formation Using the Pitting Oedema Scale
scoreStandard of Care + Geko™ TherapyStandard of Care
Baseline (pre-op)0.21 ± 0.060.14 ± 0.06
FU1 (Day 14 post-op)0.33 ± 0.070.5 ± 0.09
FU2 (Day 42 post-op)0.16 ± 0.060.28 ± 0.09
FU3 (Day 90 post-op)0.2 ± 0.060.23 ± 0.07
PrimaryAssessment of Post-operative Oedema Formation Using Bioimpedance Analysis (US Sites Only)

To assess the effect of geko™ therapy on oedema formation following foot and / or ankle surgery using a bioimpedance device to measure resistance to electrical current in both legs and calculating the percentage difference between the operated leg and the contralateral limb.

Time frame:
Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Reported as:
Mean · percent
Assessment of Post-operative Oedema Formation Using Bioimpedance Analysis (US Sites Only)
percentStandard of Care + Geko™ TherapyStandard of Care
Baseline (pre-op)-0.86 ± 1.371.04 ± 2.51
FU1 (Day 14 post-op)6.15 ± 2.228.97 ± 1.61
FU2 (Day 42 post-op)8.23 ± 2.647.43 ± 1.58
FU3 (Day 90 post-op)4.53 ± 1.45.58 ± 1.66
Statistical analysis
  • Standard of Care + Geko™ Therapy vs Standard of Care · t-test, 2 sided · p = 0.24
  • Standard of Care + Geko™ Therapy vs Standard of Care · t-test, 2 sided · p = 0.45
SecondaryAdverse Events

Incidence of Adverse Events in each group

Time frame:
From pre-surgery assessment until up to 90 days post-surgery
Reported as:
Number · events
Adverse Events
eventsStandard of Care + Geko™ TherapyStandard of Care
Adverse events2013
Adverse Device Events100
Serious Adverse Events42
Serious Adverse Device Events00
SecondaryDevice Deficiencies

To assess the number of geko device deficiencies (if any)

Time frame:
from start of geko treatment (immediately post-surgery) until up to 90 days post-surgery
Reported as:
Number · events
Device Deficiencies
eventsStandard of Care + Geko™ Therapy
Device Deficiencies11
SecondaryChange in Pain Level Using a Visual Analogue Scale (VAS) Score

Assessing pain levels using a visual analogue scale (VAS) score, where 0mm means no pain and 100mm is the worst pain possible.

Time frame:
Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Reported as:
Mean · mm
Change in Pain Level Using a Visual Analogue Scale (VAS) Score
mmStandard of Care + Geko™ TherapyStandard of Care
Baseline (pre-op)39.02 ± 4.3241.24 ± 4.82
FU1 (Day 14 post-op)30.54 ± 3.3334.31 ± 4.11
FU2 (Day 42 post-op)22.32 ± 3.4716.52 ± 2.82
FU3 (Day 90 post-op)22.08 ± 3.7116.71 ± 3.69
SecondarySurgical Wound Healing

Visually assessing the surgical wound healing status as either healed/progressing/static/deteriorating/severe.

Time frame:
From surgery until up to 90 days post-surgery
Reported as:
Count of participants · Participants
Surgical Wound Healing
ParticipantsStandard of Care + Geko™ TherapyStandard of Care
Healed2212
Progressing2122
Static01
Deteriorating00
Severe00
SecondaryChange in Analgesia Dosage

Assessing changes in dosage of recorded analgesic medication taken by the patient

Time frame:
From pre-surgery assessment until up to 90 days post-surgery
Reported as:
Number
Change in Analgesia Dosage
MeasureStandard of Care + Geko™ TherapyStandard of Care
Change in Analgesia DosageNANA
SecondaryChange in Analgesia Frequency

Analgesic medication use was recorded; however, participants were not asked to record the frequency of use. Therefore, frequency of analgesic use could not be analysed.

Time frame:
From pre-surgery assessment until up to 90 days post-surgery
Reported as:
Number · analgesia uses
Change in Analgesia Frequency
analgesia usesStandard of Care + Geko™ TherapyStandard of Care
Change in Analgesia FrequencyNANA
SecondaryChange in Patient Reported Outcomes Via Manchester-Oxford Foot & Ankle Questionnaire (MOxFQ)

Domains that are assessed in this questionnaire include walking/standing, pain and social interaction. Scores will range from 0 to 100, where 100 is most severe.

Time frame:
Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Reported as:
Mean · score
Change in Patient Reported Outcomes Via Manchester-Oxford Foot & Ankle Questionnaire (MOxFQ)
scoreStandard of Care + Geko™ TherapyStandard of Care
Baseline (pre-op)55.36 ± 3.2850.26 ± 4.3
FU1 (Day 14 post-op)59.27 ± 3.7846.63 ± 4.05
FU2 (Day 42 post-op)48.87 ± 3.3643.75 ± 4.7
FU3 (Day 90 post-op)39.72 ± 3.8136.14 ± 4.09

Adverse events

Collected over From enrollment until end of follow up (up to 90 days post-surgery). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care + Geko™ Therapy0/58 (0%)2/58 (3.4%)23/58 (39.7%)
Standard of Care0/53 (0%)2/53 (3.8%)10/53 (18.9%)
Most frequent serious events
Most frequent serious events
EventStandard of Care + Geko™ TherapyStandard of Care
Nerve pain in operated footGeneral disorders2/580/53
Surgical wound complicationsInjury, poisoning and procedural complications1/581/53
Potential peripheral nerve damage in operated footInjury, poisoning and procedural complications0/581/53
Opioid induced nauseaGastrointestinal disorders1/580/53
Most frequent other events
Showing 10 of 12
Most frequent other events
EventStandard of Care + Geko™ TherapyStandard of Care
Rash or irritation at device application siteSkin and subcutaneous tissue disorders9/580/53
Post-operative pain and/or swellingInjury, poisoning and procedural complications6/586/53
Surgical wound complicationsInjury, poisoning and procedural complications3/582/53
FallInjury, poisoning and procedural complications3/580/53
Parasthesia in operated footGeneral disorders2/581/53
Urinary tract infectionInfections and infestations0/581/53
Bruising on operated footInjury, poisoning and procedural complications0/581/53
Abdominal painGastrointestinal disorders0/581/53
Rash on operated footSkin and subcutaneous tissue disorders1/580/53
Opioid induced nauseaGastrointestinal disorders1/580/53

Baseline characteristics

Age, Customized
Age, Customized(years)Standard of Care + Geko™ TherapyStandard of CareTotal
Age at enrollment52.03 ± 14.4353.79 ± 15.8852.87 ± 15.10
Sex: Female, Male
Sex: Female, Male(Participants)Standard of Care + Geko™ TherapyStandard of CareTotal
Female443781
Male141630
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Standard of Care + Geko™ TherapyStandard of CareTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Standard of Care + Geko™ TherapyStandard of CareTotal
United States121224
United Kingdom211940
Spain252247
BMI
BMI(kg/m^2)Standard of Care + Geko™ TherapyStandard of CareTotal
Mean27.37 ± 5.0629.23 ± 6.7428.26 ± 5.97
08

Study locations

5 sites
  • Golden State Orthopedics and Spine
    Capitola, California 95010, United States
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic Barcelona
    Barcelona, 08036, Spain
  • Maidstone and Tunbridge Wells NHS Trust
    Royal Tunbridge Wells, TN2 4QJ, United Kingdom
  • The Royal National Orthopaedic Hospital NHS Trust
    Stanmore, HA7 4LP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jul 2024, 21 months.

Results were first posted in Oct 2026, 2 years 2 months after primary completion.

Of 168 interventional studies with no phase under Edema, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jun 15, 2021
StartActual
Oct 7, 2022
Primary completionActual
Jul 9, 2024
CompletionActual
Aug 5, 2024
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Sites
1 site added, 1 site removed
Show site
  • Maidstone and Tunbridge Wells NHS Trust · Royal Tunbridge Wells, United Kingdom
Show 1 removed
  • Maidstone and Tunbridge Wells NHS Trust · Tunbridge Wells, United Kingdom
Oct 7, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedAssessment of postPost-operative oedema formation usingOedema Formation Using the figureFigure-of-eight tape measurementTape MeasurementTime frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
  • EditedAssessment of postPost-operative oedema formation usingOedema Formation Using the pitting oedema scalePitting Oedema ScaleTime frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
  • EditedAssessment of postPost-operative oedema formation using bioimpedance analysisOedema Formation Using Bioimpedance Analysis (US sites onlySites Only)Time frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
Oct 7, 2026
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedIncidence of device deficienciesDevice DeficienciesTime frame: from start of geko treatment (immediately post-surgery) until up to 90 days post-surgery
  • EditedChange in pain level usingPain Level Using a visual analogue scaleVisual Analogue Scale (VAS) scoreScoreTime frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
  • EditedIncidence of surgical wound healingSurgical Wound HealingTime frame: From surgery until up to 90 days post-surgery
  • EditedChange in analgesia dosageAnalgesia DosageTime frame: From pre-surgery assessment until up to 90 days post-surgery
  • EditedChange in analgesia frequencyAnalgesia FrequencyTime frame: From pre-surgery assessment until up to 90 days post-surgery
  • EditedChange in patient reported outcomes viaPatient Reported Outcomes Via Manchester-Oxford Foot & Ankle Questionnaire (MOxFQ)Time frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
  • ChangedBefore Incidence of Adverse Events in each groupNow Adverse EventsTime frame: From pre-surgery assessment until up to 90 days post-surgery
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Maidstone and Tunbridge Wells NHS Trust · Royal Tunbridge Wells, United Kingdom
    Show 1 removed
    • Maidstone and Tunbridge Wells NHS Trust · Tunbridge Wells, United Kingdom
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedAssessment of postPost-operative oedema formation usingOedema Formation Using the figureFigure-of-eight tape measurementTape MeasurementTime frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
    • EditedAssessment of postPost-operative oedema formation usingOedema Formation Using the pitting oedema scalePitting Oedema ScaleTime frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
    • EditedAssessment of postPost-operative oedema formation using bioimpedance analysisOedema Formation Using Bioimpedance Analysis (US sites onlySites Only)Time frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedIncidence of device deficienciesDevice DeficienciesTime frame: from start of geko treatment (immediately post-surgery) until up to 90 days post-surgery
    • EditedChange in pain level usingPain Level Using a visual analogue scaleVisual Analogue Scale (VAS) scoreScoreTime frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
    • EditedIncidence of surgical wound healingSurgical Wound HealingTime frame: From surgery until up to 90 days post-surgery
    • EditedChange in analgesia dosageAnalgesia DosageTime frame: From pre-surgery assessment until up to 90 days post-surgery
    • EditedChange in analgesia frequencyAnalgesia FrequencyTime frame: From pre-surgery assessment until up to 90 days post-surgery
    • EditedChange in patient reported outcomes viaPatient Reported Outcomes Via Manchester-Oxford Foot & Ankle Questionnaire (MOxFQ)Time frame: From pre-surgery assessment until up to 90 days post-surgery → Baseline, Day 14 post-op, Day 42 post-op, Day 90 post-op
    • ChangedBefore Incidence of Adverse Events in each groupNow Adverse EventsTime frame: From pre-surgery assessment until up to 90 days post-surgery
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04927234
Lead sponsor
Firstkind Ltd
Responsible party
Sponsor
First posted
Jun 15, 2021
Start date
Oct 7, 2022
Primary completion
Jul 9, 2024
Completion
Aug 5, 2024
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Shelain Patel, MB BS BSc(Hons) FRCS
principal investigator · Royal National Orthopaedic Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion